Compare $EGRX vs $KPTI | Chartloom

Compare

$EGRX vs $KPTI

Eagle Pharmaceuticals Inc · Karyopharm Therapeutics Inc

EGRX

Eagle Pharmaceuticals Inc

KPTI

Karyopharm Therapeutics Inc

Compare $EGRX vs $KPTI

Comparing Eagle Pharmaceuticals Inc and Karyopharm Therapeutics Inc

EGRXEagle Pharmaceuticals Inc

KPTIKaryopharm Therapeutics Inc

EGRXEagle Pharmaceuticals Inc

Market cap

$13M

P/E (TTM)

1.06x

Forward P/E (NTM)

0.25x

Forward P/S (NTM)

0.05x

Rev growth (TTM)

-5.4%

YTD performance

185.3%

52W performance

49.2%

FCF yield

-74.5%

KPTIKaryopharm Therapeutics Inc

Market cap

$14M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.10x

Rev growth (TTM)

6.8%

YTD performance

-91.6%

52W performance

-89.7%

FCF yield

-476.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EGRX

KPTI

Detailed metrics comparison

EGRX

Eagle Pharmaceuticals Inc

KPTI

Karyopharm Therapeutics Inc

Market Cap

EGRX$13M

KPTI$14M

Enterprise Value

EGRX$67M

KPTI$281M

Price

EGRX$0.97

KPTI$0.61

P/E Ratio

EGRX1.06x

KPTIN/A

P/S Ratio

EGRX0.05x

KPTI0.09x

EV/Sales

EGRX0.26x

KPTI1.92x

EV/EBITDA

EGRX1.07x

KPTI0.00x

P/B Ratio

EGRX0.05x

KPTI0.36x

P/FCF Ratio

EGRXN/A

KPTIN/A

EV/FCF

EGRX-7.18x

KPTI-4.30x

PEG Ratio

EGRXN/A

KPTIN/A

Forward P/E (NTM)

EGRX0.25x

KPTIN/A

Forward P/S (NTM)

EGRX0.05x

KPTI0.10x

Revenue (TTM)

EGRX$258M

KPTI$147M

Revenue Growth (YoY)

EGRX-5.4%

KPTI6.8%

Forward Rev Growth

EGRX0.0%

KPTI27.7%

Gross Margin (TTM)

EGRX69.9%

KPTI95.9%

Operating Margin (TTM)

EGRX14.0%

KPTI0.0%

EBITDA Margin (TTM)

EGRX24.5%

KPTI-56.1%

Net Margin (TTM)

EGRX4.7%

KPTI-153.3%

FCF Margin (TTM)

EGRX-3.6%

KPTI-44.6%

Net Income (TTM)

EGRX$12M

KPTI$-225M

FCF (TTM)

EGRX$-9M

KPTI$-65M

EPS (TTM)

EGRX$0.92

KPTI-$7.77

ROE (TTM)

EGRX5.0%

KPTI-18243.0%

ROA (TTM)

EGRX3.0%

KPTI-20094.0%

ROIC (TTM)

EGRX3.9%

KPTI-6632.0%

Cash

EGRX$15M

KPTI$55M

Debt

EGRX$70M

KPTI$322M

Net Cash/Debt

EGRX$-55M

KPTI$-267M

Current Ratio (TTM)

EGRX2.16x

KPTI0.79x

Quick Ratio (TTM)

EGRX1.52x

KPTI0.71x

Debt/Equity (TTM)

EGRX0.28x

KPTI3.78x

Debt/Assets (TTM)

EGRX0.0%

KPTI0.0%

Interest Coverage (TTM)

EGRXN/A

KPTIN/A

Net Debt/EBITDA (TTM)

EGRX0.00x

KPTI0.00x

Beta

EGRX0.88

KPTI1.14

52W Performance

EGRX49.2%

KPTI-89.7%

YTD Performance

EGRX185.3%

KPTI-91.6%

% from 52W High

EGRX-74.9%

KPTI-94.5%

% from 52W Low

EGRX88081.8%

KPTI7.1%

Asset Turnover (TTM)

EGRX0.64x

KPTI1.31x

FCF Yield (TTM)

EGRX-74.5%

KPTI-476.7%

Earnings Yield (TTM)

EGRX96.0%

KPTI-1639.3%

Dividend Yield (TTM)

EGRXN/A

KPTIN/A

Rule of 40

EGRX-9.0

KPTI-37.8

EV/GP/RG

EGRXN/A

KPTI0.07

Ticker research

View EGRX research View KPTI research

Metric	EGRX Eagle Pharmaceuticals Inc	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$13M	$14M
Enterprise Value	$67M	$281M
Price	$0.97	$0.61
P/E Ratio	1.06x	N/A
P/S Ratio	0.05x	0.09x
EV/Sales	0.26x	1.92x
EV/EBITDA	1.07x	0.00x
P/B Ratio	0.05x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.18x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	0.25x	N/A
Forward P/S (NTM)	0.05x	0.10x
Revenue & Growth
Revenue (TTM)	$258M	$147M
Revenue Growth (YoY)	-5.4%	6.8%
Forward Rev Growth	0.0%	27.7%
Profitability
Gross Margin (TTM)	69.9%	95.9%
Operating Margin (TTM)	14.0%	0.0%
EBITDA Margin (TTM)	24.5%	-56.1%
Net Margin (TTM)	4.7%	-153.3%
FCF Margin (TTM)	-3.6%	-44.6%
Net Income (TTM)	$12M	$-225M
FCF (TTM)	$-9M	$-65M
EPS (TTM)	$0.92	-$7.77
ROE (TTM)	5.0%	-18243.0%
ROA (TTM)	3.0%	-20094.0%
ROIC (TTM)	3.9%	-6632.0%
Financial Health
Cash	$15M	$55M
Debt	$70M	$322M
Net Cash/Debt	$-55M	$-267M
Current Ratio (TTM)	2.16x	0.79x
Quick Ratio (TTM)	1.52x	0.71x
Debt/Equity (TTM)	0.28x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.88	1.14
52W Performance	49.2%	-89.7%
YTD Performance	185.3%	-91.6%
% from 52W High	-74.9%	-94.5%
% from 52W Low	88081.8%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.64x	1.31x
FCF Yield (TTM)	-74.5%	-476.7%
Earnings Yield (TTM)	96.0%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-9.0	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View EGRX research	View KPTI research

Valuation

P/E Ratio

EGRX

1.06x

P/S Ratio

EGRX

0.05x

KPTI

0.09x

EV/FCF

EGRX

-7.18x

KPTI

-4.30x

Growth & revenue

Revenue Growth TTM

KPTI

6.8%

EGRX

-5.4%

Forward Revenue Growth

KPTI

27.7%

EGRX

0.0%

Profitability & performance

Gross Margin

KPTI

95.9%

EGRX

69.9%

ROE

EGRX

5.0%

KPTI

-18243.0%

FCF Yield %

EGRX

-74.5%

KPTI

-476.7%

52-Week Performance

EGRX

49.2%

KPTI

-89.7%

Detailed metrics comparison

EGRX

Eagle Pharmaceuticals Inc

KPTI

Karyopharm Therapeutics Inc

Market Cap

EGRX$13M

KPTI$14M

Enterprise Value

EGRX$67M

KPTI$281M

Price

EGRX$0.97

KPTI$0.61

P/E Ratio

EGRX1.06x

KPTIN/A

P/S Ratio

EGRX0.05x

KPTI0.09x

EV/Sales

EGRX0.26x

KPTI1.92x

EV/EBITDA

EGRX1.07x

KPTI0.00x

P/B Ratio

EGRX0.05x

KPTI0.36x

P/FCF Ratio

EGRXN/A

KPTIN/A

EV/FCF

EGRX-7.18x

KPTI-4.30x

PEG Ratio

EGRXN/A

KPTIN/A

Forward P/E (NTM)

EGRX0.25x

KPTIN/A

Forward P/S (NTM)

EGRX0.05x

KPTI0.10x

Revenue (TTM)

EGRX$258M

KPTI$147M

Revenue Growth (YoY)

EGRX-5.4%

KPTI6.8%

Forward Rev Growth

EGRX0.0%

KPTI27.7%

Gross Margin (TTM)

EGRX69.9%

KPTI95.9%

Operating Margin (TTM)

EGRX14.0%

KPTI0.0%

EBITDA Margin (TTM)

EGRX24.5%

KPTI-56.1%

Net Margin (TTM)

EGRX4.7%

KPTI-153.3%

FCF Margin (TTM)

EGRX-3.6%

KPTI-44.6%

Net Income (TTM)

EGRX$12M

KPTI$-225M

FCF (TTM)

EGRX$-9M

KPTI$-65M

EPS (TTM)

EGRX$0.92

KPTI-$7.77

ROE (TTM)

EGRX5.0%

KPTI-18243.0%

ROA (TTM)

EGRX3.0%

KPTI-20094.0%

ROIC (TTM)

EGRX3.9%

KPTI-6632.0%

Cash

EGRX$15M

KPTI$55M

Debt

EGRX$70M

KPTI$322M

Net Cash/Debt

EGRX$-55M

KPTI$-267M

Current Ratio (TTM)

EGRX2.16x

KPTI0.79x

Quick Ratio (TTM)

EGRX1.52x

KPTI0.71x

Debt/Equity (TTM)

EGRX0.28x

KPTI3.78x

Debt/Assets (TTM)

EGRX0.0%

KPTI0.0%

Interest Coverage (TTM)

EGRXN/A

KPTIN/A

Net Debt/EBITDA (TTM)

EGRX0.00x

KPTI0.00x

Beta

EGRX0.88

KPTI1.14

52W Performance

EGRX49.2%

KPTI-89.7%

YTD Performance

EGRX185.3%

KPTI-91.6%

% from 52W High

EGRX-74.9%

KPTI-94.5%

% from 52W Low

EGRX88081.8%

KPTI7.1%

Asset Turnover (TTM)

EGRX0.64x

KPTI1.31x

FCF Yield (TTM)

EGRX-74.5%

KPTI-476.7%

Earnings Yield (TTM)

EGRX96.0%

KPTI-1639.3%

Dividend Yield (TTM)

EGRXN/A

KPTIN/A

Rule of 40

EGRX-9.0

KPTI-37.8

EV/GP/RG

EGRXN/A

KPTI0.07

Ticker research

View EGRX research View KPTI research

Metric	EGRX Eagle Pharmaceuticals Inc	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$13M	$14M
Enterprise Value	$67M	$281M
Price	$0.97	$0.61
P/E Ratio	1.06x	N/A
P/S Ratio	0.05x	0.09x
EV/Sales	0.26x	1.92x
EV/EBITDA	1.07x	0.00x
P/B Ratio	0.05x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.18x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	0.25x	N/A
Forward P/S (NTM)	0.05x	0.10x
Revenue & Growth
Revenue (TTM)	$258M	$147M
Revenue Growth (YoY)	-5.4%	6.8%
Forward Rev Growth	0.0%	27.7%
Profitability
Gross Margin (TTM)	69.9%	95.9%
Operating Margin (TTM)	14.0%	0.0%
EBITDA Margin (TTM)	24.5%	-56.1%
Net Margin (TTM)	4.7%	-153.3%
FCF Margin (TTM)	-3.6%	-44.6%
Net Income (TTM)	$12M	$-225M
FCF (TTM)	$-9M	$-65M
EPS (TTM)	$0.92	-$7.77
ROE (TTM)	5.0%	-18243.0%
ROA (TTM)	3.0%	-20094.0%
ROIC (TTM)	3.9%	-6632.0%
Financial Health
Cash	$15M	$55M
Debt	$70M	$322M
Net Cash/Debt	$-55M	$-267M
Current Ratio (TTM)	2.16x	0.79x
Quick Ratio (TTM)	1.52x	0.71x
Debt/Equity (TTM)	0.28x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.88	1.14
52W Performance	49.2%	-89.7%
YTD Performance	185.3%	-91.6%
% from 52W High	-74.9%	-94.5%
% from 52W Low	88081.8%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.64x	1.31x
FCF Yield (TTM)	-74.5%	-476.7%
Earnings Yield (TTM)	96.0%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-9.0	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View EGRX research	View KPTI research